fbpx

Year

2015
Funding from the Lundbeck Foundation ensures joint professorship in drug delivery and nanomedicine between the University of Copenhagen and the University of British Columbia. The professorship will lead to the creation of new and improved drugs.
SAN DIEGO, Jan. 9, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that on January 5, 2015 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 13,500 shares...
Vtesse to collaborate with National Institutes of Health on development of VTS-270 for Niemann-Pick Disease Type C and other novel drugs for life-threatening rare diseases
2,000L Demonstration Batch Completed at Lonza, Houston FacilitySAN DIEGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has conducted initial scale up of its viral manufacturing process for MYDICAR (AAV1/SERCA2a) to commercial scale.
SAN DIEGO, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has been added to the NASDAQ Biotechnology Index, through the annual update that will become effective prior to market open on Monday, December 22, 2014.The NASDAQ...
1 5 6 7

Nyheder

New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020
A female dog may well be the answer
24. January 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge